The Role of Endothelin 1 as a Marker of Renal Impairment in Sickle Cell Disease

Recruiting

• Conditions: Sickle Cell Disease

• Registration Number: NCT06158945
• Lead Sponsor: Sohag University

Brief Summary

Sickle cell disease (SCD) refers to a group of hemoglobinopathies that include mutations in the gene encoding the beta subunit of hemoglobin. Within the umbrella of SCD, many subgroups exist, namely sickle cell anemia (SCA), hemoglobin SC disease (HbSC), and hemoglobin sickle-beta-thalassemia (beta-thalassemia positive or beta-thalassemia negative). Several other minor variants within the group of SCDs also, albeit not as common as the varieties mentioned above. It is essential to mention the sickle cell trait (HbAS), which carries a heterozygous mutation and seldom presents clinical signs or symptoms. Sickle cell anemia is the most common form of SCD

Detailed Description

Not available

Study Timeline

• Study Start: 2023-10-24
• Status Verified: 2023-11
• Study First Submitted: 2023-11-28
• Study First Submitted QC: 2023-12-05
• Last Update Submitted: 2023-12-05
• Study First Posted: 2023-12-06
• Last Update Posted: 2023-12-06
• Primary Completion: 2024-10-23
• Study Completion: 2024-10-23

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• The patients fulfilling all the following criteria will be included:
• Patients with sickle cell disease in the age range of 1-18years.

Exclusion Criteria

• Patients diagnosed to have coexistent renal disease before the study

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
renal affection in sickle cell patients	1 year	assessment of urinary endothelin 1 as a marker of renal impairment in sickle cell patients

Trial Locations

Locations (1)

Sohag university Hospital; 🇪🇬 Sohag, Egypt